What is AnchorDx?
AnchorDx, also known as Guangzhou Benchmark Medical Co., Ltd., operates as a specialized provider of high-throughput sequencing clinical applications. The company is dedicated to building a world-class research and development platform that integrates advanced genomic sequencing with clinical diagnostics. By focusing on precision medicine, AnchorDx aims to deliver holistic solutions that improve patient outcomes and streamline diagnostic workflows. Its market position is defined by its ability to handle large-scale genomic data, positioning it as a critical partner for healthcare providers and research institutions seeking to implement data-driven medical strategies.
How much funding has AnchorDx raised?
AnchorDx has raised a total of $68M across 2 funding rounds:
Series B
$28M
Series C
$40M
Series B (2017): $28M with participation from Dimensions Capital and Sijia Jianxin Fund
Series C (2021): $40M led by OrbiMed Advisors LLC, Northern Light Venture Capital, Dimensions Capital, WuXi Huiying Investment, and KingMed Diagnostics
Key Investors in AnchorDx
OrbiMed Advisors LLC
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics to support innovation at various stages of development.
Northern Light Venture Capital
NLVC is a technology-centric venture capital firm that supports entrepreneurs in enterprise and healthcare sectors, emphasizing opportunities that drive digital transformation and global impact.
6 Dimensions Capital
6 Dimensions Capital is an investment firm focused on innovative life science companies, operating with a strategic presence in both China and the United States.
What's next for AnchorDx?
Looking ahead, the strategic deployment of the $40M capital will likely focus on expanding the company's operational footprint and enhancing its proprietary sequencing technologies. As AnchorDx moves beyond its current development phase, the focus will shift toward commercializing its diagnostic pipeline and strengthening its international presence. The backing from top-tier healthcare investors suggests a clear path toward scaling its enterprise-level solutions, with an emphasis on regulatory milestones and the integration of artificial intelligence into its diagnostic platforms. This strategic roadmap is designed to maintain the company's competitive edge in the rapidly evolving landscape of molecular diagnostics and personalized healthcare.
See full AnchorDx company page
